The Neuroprotective Role of A2A Adenosine Purinoceptor Modulation as a Strategy Against Glioblastoma

• Published in: Brain sciences 2024-12, Vol.14 (12), p.1286
• Main Authors: Simões, Júlia Leão Batista, Braga, Geórgia de Carvalho, Fontana, Michelli, Assmann, Charles Elias, Bagatini, Margarete Dulce
• Format: Article
• Language: English
• Subjects: A2A purinoceptor; Adenosine; Adenosine A2A receptors; Adjuvants; Angiogenesis; Cancer therapies; Cell growth; Cytokines; Dopamine; Drug approval; Drug development; FDA approval; Glioblastoma; Glioblastoma multiforme; Glioma; Growth factors; Hypoxia; Immune system; Istradefylline; Lymphocytes; Neuroblastoma; Neurodegenerative diseases; Neuromodulation; Neuroprotection; Parkinson's disease; Permeability; Prognosis; purinergic system; Restless legs syndrome; Review; Tumors
• ISSN: 2076-3425; 2076-3425
• DOI: 10.3390/brainsci14121286

Glioblastoma (GBM) is a highly lethal type of cancer, frequently presenting an unfavorable prognosis. The current treatment options for this neoplasia are still limited, highlighting the need for further research evaluating new drugs to treat GBM or to serve as an adjuvant to improve the efficiency of currently used therapies. In this sense, the inhibition of A2A receptors in the brain has presented a neuroprotective role for several diseases, such as neurodegenerative conditions, and it has been suggested as a possible pharmacological target in some types of cancer; thus, it also can be underscored as a potential target in GBM. Recently, Istradefylline (IST) was approved by the FDA for treating Parkinson's disease, representing a safe drug that acts through the inhibition of the A2A receptor, and it has also been suggested as an antineoplastic drug. Therefore, this work aims to explore the effects of A2A receptor inhibition as a therapy for GBM and assess the feasibility of this blockage occurring through the effects of IST.